FDA Adverse Event Reporting Services

The FDA adverse event reporting system is the framework used to collect, assess, and submit information about device-related deaths, serious injuries, malfunctions, and other safety issues. For medical device manufacturers, this typically involves Medical Device Reporting under 21 CFR Part 803, supported by complaint handling, investigation records, and post-market surveillance processes that help identify reportable events and emerging safety trends.

Some adverse events must be reported to the FDA, but not every complaint automatically qualifies. Manufacturers must assess whether an event meets MDR criteria, such as involving a death, serious injury, or a malfunction that could cause serious harm if it recurred. A documented reportability assessment is essential because missed reporting deadlines or unsupported decisions can create significant compliance risk during inspections.

Events are typically reportable when a medical device may have caused or contributed to a death or serious injury, or when a malfunction would be likely to cause or contribute to serious harm if it happened again. Reportability depends on the facts of the case, device function, investigation findings, and the regulatory criteria in 21 CFR Part 803, not simply on whether a complaint was received.

Submission timing depends on the type of report and the circumstances involved. Standard MDR timelines often require prompt action once reportability is known, and certain situations may trigger accelerated reporting obligations. Companies need a disciplined intake, triage, and review process so complaints are assessed quickly, investigations are documented properly, and required reports are prepared before deadlines are missed.

Complaint handling is usually the starting point for adverse event reporting. Incoming complaints must be reviewed, classified, investigated, and evaluated for reportability. A strong complaint system links each case to investigation records, risk management, and post-market surveillance so potential MDR events are not overlooked. FDA inspectors often examine whether complaint files support timely, consistent, and well-documented reporting decisions.

Yes. Elexes supports structured reportability assessments by reviewing the event details, complaint record, investigation status, and applicable FDA criteria. The team documents the regulatory rationale behind each decision and helps prepare submissions when reporting is required. This approach helps manufacturers improve consistency, reduce uncertainty, and maintain defensible records that stand up to internal review and external inspection.

Companies should maintain the complaint file, investigation records, device details, event chronology, supporting evidence, reportability assessment, regulatory rationale, and any submitted MDR documentation. Even when an event is determined to be non-reportable, the basis for that decision should be clearly documented. Complete records help demonstrate that the company followed a systematic process rather than making unsupported or inconsistent judgments.

Companies often outsource reporting support to gain specialized regulatory expertise, improve turnaround times, and strengthen documentation quality without expanding internal headcount. External support can be especially valuable when complaint volumes increase, internal teams lack MDR experience, or the organization needs help integrating complaint handling, PMS, and reportability decisions into a more consistent and inspection-ready post-market system.